Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.

Published

Journal Article

The high prevalence of herpes simplex virus 2 (HSV-2) infections in humans necessitates the development of a safe and effective vaccine that will need to induce vigorous T-cell responses to control viral infection and transmission. We designed rAd-gD2, rAd-gD2ΔUL25, and rAd-ΔUL25 to investigate whether recombinant replication-defective adenoviruses vaccine could induce specific T-cell responses and protect mice against intravaginal HSV-2 challenge compared with FI-HSV-2. In the present study, recombinant adenovirus-based HSV-2 showed higher reductions in mortality and stronger antigen-specific T-cell responses compared with FI-HSV-2 and the severity of genital lesions in mice immunized with rAd-gD2ΔUL25 was significantly decreased by eliciting IFN-γ-secreting T-cell responses compared with rAd-gD2 and rAd-ΔUL25 groups. Our results demonstrated the immunogenicity and protective efficacy of recombinant adenovirus vaccines in acute HSV-2 infection following intravaginal challenge in mice.

Full Text

Duke Authors

Cited Authors

  • Liu, W; Zhou, Y; Wang, Z; Zhang, Z; Wang, Q; Su, W; Chen, Y; Zhang, Y; Gao, F; Jiang, C; Kong, W

Published Date

  • May 2017

Published In

Volume / Issue

  • 61 / 5

Start / End Page

  • 176 - 184

PubMed ID

  • 28378925

Pubmed Central ID

  • 28378925

Electronic International Standard Serial Number (EISSN)

  • 1348-0421

International Standard Serial Number (ISSN)

  • 0385-5600

Digital Object Identifier (DOI)

  • 10.1111/1348-0421.12482

Language

  • eng